Kiniksa officer Megna proposes $4.56M share sale

The listed shares comprise 16,365 shares from a restricted stock lapse and 31,175 from an employee stock option exercise.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) is named as issuer in officer Michael R. Megna's Rule 144 notice covering the proposed sale of 47,540 Class A ordinary shares through Charles Schwab & Co., Inc. The listed aggregate market value is $4,559,561.00, with October 30, 2026 as the approximate sale date; the shares may be sold over various dates.

Key Figures

Shares proposed for sale: 47,540 shares Aggregate market value: $4,559,561.00 Restricted stock lapse: 16,365 shares +3 more

6 metrics

Shares proposed for sale 47,540 shares Class A ordinary shares

Aggregate market value $4,559,561.00 Shares proposed for sale

Restricted stock lapse 16,365 shares Class A ordinary shares listed for sale

Employee stock option exercise 31,175 shares Class A ordinary shares listed for sale

Shares sold during the past three months 4,600 shares Reported sales by Michael R. Megna

Aggregate market value $369,380.00 Shares sold during the past three months

Key Terms

Rule 144, Restricted Stock Lapse, Employee Stock Option Exercise, Cashless Exercise, +1 more

5 terms

Rule 144 regulatory

"Michael R. Megna's Rule 144 notice"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Lapse technical

"16,365 shares; Restricted Stock Lapse"

Employee Stock Option Exercise technical

"31,175 shares; Employee Stock Option Exercise"

Cashless Exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

Equity Compensation financial

"Restricted Stock Lapse; Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares did Michael R. Megna report for sale?

Michael R. Megna's notice covers 47,540 Kiniksa Class A ordinary shares, with an aggregate market value of $4,559,561.00 and an approximate sale date of October 30, 2026.

What makes up the 47,540 KNSA shares in the notice?

The listed shares comprise 16,365 Class A ordinary shares under “Restricted Stock Lapse” and 31,175 shares under “Employee Stock Option Exercise.” The associated entries also describe equity compensation and broker payment for cashless exercise.

How many KNSA shares did Michael R. Megna sell during the past three months?

The past-three-months section lists 4,600 Kiniksa Class A ordinary shares sold by Michael R. Megna, with an aggregate market value of $369,380.00.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 06:15 PM EDT Accepted by SEC EDGAR 10/30/2026 - 06:14 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001464583
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Megna Michael R
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	47540	4559561.00	48836965	10/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	03/16/2024	Restricted Stock Lapse - See Remarks	Kiniksa Pharmaceuticals International, plc			16365	03/16/2024	Equity Compensation
Class A ordinary shares	10/30/2026	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			31175	10/30/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael R Megna 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	09/03/2026	4600	369380.00

144: Remarks and Signature

Remarks	The shares reported on this filing were acquired and paid for between 03/16/2024 and 09/01/2026 and may be sold over various dates.
Date of Notice	10/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	07/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Michael R Megna
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)